Today: 30 June 2026
GameStop Stock Pops After Ryan Cohen Teases “Very, Very, Very Big” Consumer Buyout
31 January 2026
1 min read

GameStop Stock Pops After Ryan Cohen Teases “Very, Very, Very Big” Consumer Buyout

New York, Jan 31, 2026, 11:24 (EST)

  • GameStop CEO Ryan Cohen revealed he’s chasing a big acquisition—a larger public consumer company.
  • Shares climbed 4.78% Friday, ending the day at $23.88
  • Cohen’s stock-option award kicks in only if GameStop reaches a $100 billion market cap and achieves $10 billion in cumulative EBITDA

GameStop CEO Ryan Cohen revealed the company is targeting a “very, very, very big” acquisition of a publicly traded consumer firm, one far larger than GameStop itself. He described the deal as “transformational” during an interview with CNBC. Cohen emphasized he’s after an undervalued company with a “sleepy management team,” though he didn’t drop any names. Shares of GameStop jumped 4.78% on Friday, closing at $23.88, according to Yahoo Finance. TipRanks

Cohen’s remarks arrive as he attempts to reposition GameStop as a Berkshire Hathaway-style holding company, anchored by a massive cash reserve. He told The Wall Street Journal this move could be “genius or totally, totally foolish,” according to Investing.com. The report noted that GameStop holds about $9 billion in cash, and Cohen called Michael Burry “one of the few investors I respect.” Investing.com

Earlier this month, GameStop’s board granted Cohen a stock option award tied to performance, covering 171,537,327 shares at an exercise price of $20.66. He won’t receive any salary or cash bonus. The options vest only if the company reaches a $20 billion market cap and $2 billion in cumulative EBITDA—earnings before interest, taxes, depreciation, and amortization. The final tranche kicks in if GameStop hits a $100 billion market value and $10 billion in cumulative EBITDA. Shareholder approval is still pending, with a special meeting expected in March or April, the company said.

Skeptics are already voicing doubts. Michael Pachter, equity research managing director at Wedbush Securities, told Fortune, “I’d say no, not going to happen.” Cohen, who founded online pet retailer Chewy before its $3.35 billion acquisition by PetSmart, is now aiming for a far bigger comeback at GameStop. Fortune

GameStop’s annual revenue has dropped over 35% since 2022, with its stock plunging roughly 80% from the highs seen during the 2021 meme-stock surge, Reuters reported earlier this month. The new compensation package mirrors the long-term stock-option deal given to Tesla CEO Elon Musk and follows sharp cost reductions and store closures that have helped the company return to profitability, according to the report.

Cohen’s strategy is straightforward: acquire a larger asset, turn it around, then rely on the market to take it from there. This marks a clear departure from the GameStop narrative many investors still recall.

Deals that size are complicated, even when the target company is on board. When the buyer is the smaller party, things can get odd quickly—financing, control, and governance often overshadow the asset itself.

Here’s the fundamental issue: no target has been identified. Cohen didn’t provide a timeline or a price range, and the company hasn’t revealed any process details, advisers, or terms—only a vague promise and plenty of flexibility.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • HCW Biologics (HCWB) Back in Step with Nasdaq Bid Price Rule
    June 30, 2026, 9:25 AM EDT. HCW Biologics Inc. (Nasdaq: HCWB) is back in compliance with Nasdaq's minimum bid price rule, with the exchange's Hearings Panel signing off as of June 29, 2026. The panel said the company now meets Listing Rule 5550(a)(2) and will stay under a monitoring period until June 17, 2027. HCW Biologics plans a one-for-six reverse stock split on June 30, 2026, to stay compliant. The biotech works on fusion immunotherapeutics for chronic inflammation diseases like autoimmune disorders and cancer. Staying listed on Nasdaq supports its clinical and business push.
C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers
Previous Story

C3.ai stock price slips in premarket as Automation Anywhere merger-talk report lingers

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday
Next Story

Reckitt Benckiser shares jump, but an ex-dividend reset looms on Monday

Go toTop